Floatz logo

Vistusertib

Glioblastoma Multiforme

Canadian Cancer Trials GroupSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

354 Active assets in the Glioblastoma Multiforme cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 3BB

View all 50 →

Same molecule, other indications

Vistusertib is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
56 / 100
View asset →
breast cancerDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →